Current Scenario of Digitalization in Pharmaceutical Industry
DOI:
https://doi.org/10.37285/ijpsn.2024.17.1.9Abstract
Digitalization is playing an important role in all business sectors. Every sector and industry first oppose the reforms being introduced but law of life is always for the better. Indian pharma industry is still in the early stages of digitalization, it induces transparency, productivity and speeding up the activities. Hence, there is an urgent need of digitalization in traditional and new drug development process. The success of digitalization in pharmaceutical industry depends upon implementation of aspects of good manufacturing practice. In this review, we focused on importance of digitalization in pharma sector in sales improvement, process digitalization, principles of GMP and CDMO digitalization process.
Downloads
Metrics
Keywords:
Pharmaceutical industry, digitalization, transformation, Sales, market size
Published
How to Cite
Issue
Section
References
Abedellah A, Noordin M, Zaki AA. Pharmaceutical good manufacturing practice regulatory affairs in Sudan: continuous debate between regulatory authority and manufacturers. Pharmaceut. Reg. Affairs 2016; 5(166): 2.
Abhinaya N, Thunga G, Muddukrishna BS, Pai R, Shenoy UR, Khan S, Pai KG. A research on effective management of manufacturing defects to avoid product recalls: a challenge to pharmaceutical industry. Research Journal of Pharmacy and Technology. 2019; 12(12): 6124-32.
Abou-El-Enein M, Romhild A, Kaiser D, Beier C, Bauer G, Volk HD, Reinke P. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy. 2013; 15(3):362-83.
Aghayan HR, Arjmand B, Burger SR. GMP facilities for clinical cell therapy product manufacturing: a brief review of requirements and design considerations. Perinatal Tissue-Derived Stem Cells. 2016: 215-27.
Alagarsamy S, Kandasamy R, Subbiah L, Palanisamy S. Applications of Internet of Things in Pharmaceutical Industry. Available at SSRN 3441099. 2019 Aug 22.
Alloghani M, Al-Jumeily D, Hussain A, Aljaaf AJ, Mustafina J, Petrov E. Healthcare services innovations based on the state of the art technology trend industry 4.0. 11th International Conference on Developments in e-Systems Engineering (DeSE) 2018 64-70). IEEE.
Anthony Jnr B, Abbas Petersen S. Examining the digitalisation of virtual enterprises amidst the COVID-19 pandemic: a systematic and meta-analysis. Enterprise Information Systems. 2021; 15(5): 617-50.
Arden NS, Fisher AC, Tyner K, Lawrence XY, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. International Journal of Pharmaceutics. 2021; 602:120554.
Awad A, Trenfield SJ, Gaisford S, Basit AW. 3D printed medicines: A new branch of digital healthcare. International journal of pharmaceutics. 2018; 548(1):586-96.
Awad A, Trenfield SJ, Goyanes A, Gaisford S, Basit AW. Reshaping drug development using 3D printing. Drug discovery today. 2018; 23(8):1547-55.
Ayati N, Saiyarsarai P, Nikfar S. Short and long term impacts of COVID-19 on the pharmaceutical sector. DARU Journal of Pharmaceutical Sciences. 2020; 28(2): 799-805.
Hole G, Hole AS, McFalone-Shaw I. Digitalization in pharmaceutical industry: What to focus on under the digital implementation process. International Journal of Pharmaceutics: X. 2021; 3:100095.
Berthon PR, Pitt LF, Plangger K, Shapiro D. Marketing meets Web 2.0, social media, and creative consumers: Implications for international marketing strategy. Business horizons. 2012; 55(3): 261-71.
Reddy MV, Ganesh GN, Ahmed SS, Rajendra PK, Babu E. Research on Pharmaceutical Product Life Cycle Management Challenges Faced by Generic Manufacturers for US Approval.2012; 10(2): 35-67.
Akar E, Topcu B. An examination of the factors influencing consumers' attitudes toward social media marketing. Journal of internet commerce. 2011; 10(1): 35-67.
Brynjolfsson E, Schrage M. The new, faster face of innovation. The Wall Street Journal. 2009 : 4(3); 1-2.
Budden CB, Anthony JF, Budden MC, Jones MA. Managing the evolution of a revolution: Marketing implications of Internet media usage among college students. College Teaching Methods & Styles Journal (CTMS). 2007; 3(3): 5-10.
Chen Y, Fay S, Wang Q. The role of marketing in social media: How online consumer reviews evolve. Journal of interactive marketing. 2011; 25(2): 85-94.
Kaplan AM, Haenlein M. Users of the world, unite! The challenges and opportunities of Social Media. Business horizons. 2010; 53(1): 59-68.
Kozinets RV, De Valck K, Wojnicki AC, Wilner SJ. Networked narratives: Understanding word-of-mouth marketing in online communities. Journal of marketing. 2010; 74(2): 71-89.
Leeflang PS, Verhoef PC, Dahlstrom P, Freundt T. Challenges and solutions for marketing in a digital era. European management journal. 2014; 32(1): 1-2.
Reibstein DJ, Day G, Wind J. Guest editorial: is marketing academia losing its way. Journal of Marketing. 2009; 73(4): 1-3.
Rigby D. The future of shopping. Harvard business review. 2011; 89(12): 65-76.
BenMoussa C. Dealing with the barriers to performance through value-adding mobile solutions: Case study of the sales force of a pharmaceutical company. In2007 40th Annual Hawaii International Conference on System Sciences (HICSS'07) 2007 (pp. 50-50). IEEE.
Chen CW, Tseng CP, Lee KL, Yang HC. Conceptual framework and research method for personality traits and sales force automation usage. Scientific Research and Essays. 2011; 6(17): 3784-93.
DeLone WH, McLean ER. The DeLone and McLean model of information systems success: a ten-year update. Journal of management information systems. 2003; 19(4): 9-30.
Wankhede AB. Evaluating the effect of digitalization on the sales force of pharmaceutical industry. Economics and Applied Informatics. 2018(2): 21-9.
Manjramkar J. Information Technology (it) Tools and Indian Health Care Sector-the Present Status and Roadmap. Available at SSRN 2716191. 2016.
McGill T, Hobbs V, Klobas J. User developed applications and information systems success: A test of DeLone and McLean's model. Information Resources Management Journal (IRMJ). 2003; 16(1): 24-45.
Petter S, DeLone WH, McLean ER. Measuring information systems success: models, dimensions, measures, and interrelationships. European journal of information systems. 2008; 17(3): 236-63.
Polasik M, Wisniewski TP. Empirical analysis of internet banking adoption in Poland. International Journal of bank marketing. 2009.
Engle RL, Barnes ML. Sales force automation usage, effectiveness, and cost benefit in Germany, England and the United States. Journal of Business & Industrial Marketing. 2000.
Sharif K. Impact of information and communication technologies on sales representative internal and external relationships—A study of the UK pharmaceutical sector. Journal of Medical Marketing. 2008; 8(4): 341-55.
Wankhede AB. Evaluating the effect of digitalization on the sales force of pharmaceutical industry. Economics and Applied Informatics. 2018(2): 21-9.
Zikmund WG, McLeod R, Gilbert FW. Customer relationship management: Integrating marketing strategy and information technology. Wiley; 2003.
Jackson NM. The Politics of Care: Black Community Activism in England and the United States, 1975–1985. The Ohio State University; 2012.
Alt R. Transformation in the Pharmaceutical Industry) Developing Customer Orientation at Pharma Corp. BLED 2003 Proceedings. 2003; 31:59.
Baker LC, Johnson SJ, Macaulay D, Birnbaum H. Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings. Health Affairs. 2011; 30(9): 1689-97.
Brown MT, Bussell JK. Medication adherence: WHO cares?InMayo clinic proceedings. 2011; 86(4): 304-314.
Forissier T, Firlik K, Qin K, Karkera S, Hadzhiyski O. Estimated annual pharmaceutical revenue loss due to medication non-adherence. Capgemini Consulting &HealthPrize Technologies. 2012.
Westerman G, Calmejane C, Bonnet D, Ferraris P, McAfee A. Digital Transformation: A roadmap for billion-dollar organizations. MIT Center for digital business and Capgemini consulting. 2011; 1: 1-68.
Carroll S. Goodbye blockbuster medicines; hello new pharmaceutical business models. Pharmaceutical journal. 2009; 282(7555): 681-2.
Chaudhry B, Wang J, Wu S, Maglione M, Mojica W, Roth E, Morton SC, Shekelle PG. Systematic review: impact of health information technology on quality, efficiency, and costs of medical care. Annals of internal medicine. 2006; 144(10): 742-52.
Dzau VJ, Ginsburg GS, Van Nuys K, Agus D, Goldman D. Aligning incentives to fulfill the promise of Personalized Medicine. Lancet (London, England). 2015; 385(9982): 2118.
Mulinari S, Martinon L, Jachiet PA, Ozieranski P. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries. Health Policy. 2021; 125(7): 915-22.
Neumann PJ, Sullivan SD, Westrich K, Dubois RW. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am. J. Manag. Care. 2015; 21(9): 632-40.
Gilbert J, Henske P, Singh A. Rebuilding big pharma's business model. In vivo-New York then Norwalk. 2003; 21(10): 73-80.
Goldschmidt PG. HIT and MIS: implications of health information technology and medical information systems. Communications of the ACM. 2005 Oct 1; 48(10): 68-74.
Hulshof JA. Sustainable health care systems: the role of therapeutic value and value-based pricing. Value in Health. 2014; 17(7): A452.
Iglehart JK. Connected health: emerging disruptive technologies. Health affairs. 2014 Feb 1;33(2):190.
Aitken M, Gorokhovich L. Advancing the responsible use of medicines: applying levers for change. Available at SSRN 2222541. 2012.
Jain SH. How pharma can offer more than pills. Harvard Business Review. 2015; 23.
Jorgensen JT. Companion diagnostics and the drug–diagnostic co-development model. Drug Development Research. 2012; 73(7): 390-7.
Lancet T. Lessons from Lipitor and the broken blockbuster drug model. Lancet (London, England). 2011; 378(9808): 1976.
Littig B. interviewing the elite—interviewing experts: is there a difference. Interviewing experts 2009 (pp. 98-113). Palgrave Macmillan, London.
Maciosek MV, Coffield AB, Flottemesch TJ, Edwards NM, Solberg LI. Greater use of preventive services in US health care could save lives at little or no cost. Health Affairs. 2010; 29(9): 1656-60.
Cattell J, Chilukuri S, Knott D. Beyond the pill: creating medical value through technology enablement. Operations for the executive suite. Opening new horizons for current and future pharma leaders. McKinsey & Company. 2012: 85-94.
Magrini N, Font M. Direct to consumer advertising of drugs in Europe. BMJ. 2007; 335(7619): 526.
Malik NN, Khan Y. Personalized medicine: potential impact on the biopharmaceutical industry. Drug discovery today. 2010; 15(21-22): 881-3.
Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Affairs. 2011; 30(12): 2329-37.
Osterwalder A, Pigneur Y. Business Model Geberation. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews Drug discovery. 2010;9(3):203-14.
Persson U, Jonsson B. The end of the international reference pricing system. Applied health economics and health policy. 2016; 14(1): 1-8.
Porter ME, Teisberg EO. Redefining competition in health care. Harvard business review. 2004: 64-77.
PricewaterhouseCoopers P. Challenging business models, 2009.
Bigelow JH, Fonkych K, Fung C, Wang J. Analysis of healthcare interventions that change patient trajectories. Rand Corporation; 2005.
Mattke S, Klautzer L, Mengistu T. Medicines as a service: A new commercial model for big pharma in the post blockbuster world. Rand health quarterly. 2012; 2(2).
Rasmussen KA, Foss NJ. Business model innovation in the pharmaceutical industry: The supporting role of organizational design.
Markets HE. Global Forecast to 2024. Research and Markets. 2019.
Ruof J, Schwartz FW, Schulenburg JM, Dintsios CM. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation. The European Journal of Health Economics. 2014; 15(6): 577-89.
Sackett DL, Rosenberg WM, Gray JM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. Bmj. 1996; 312(7023): 71-2.
Shah NH, Tenenbaum JD. Focus on translational bioinformatics: The coming age of data-driven medicine: translational bioinformatics' next frontier. Journal of the American Medical Informatics Association: JAMIA. 2012; 19(e1): e2.
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Medical care. 2005; 521-30.
Gupta A, Schumacher J, Sinha S. Digital health: A way for pharma companies to be more relevant in healthcare. New York, New York, USA. 2013.
Sullivan SD, Watkins J, Sweet B, Ramsey SD. Health technology assessment in health care decisions in the United States. Value in Health. 2009; 12: S39-44.
Swan M. Emerging patient-driven health care models: an examination of health social networks, consumer personalized medicine and quantified self-tracking. International journal of environmental research and public health. 2009; 6(2): 492-525.
Sabate E, Sabate E, editors. Adherence to long-term therapies: evidence for action. World Health Organization; 2003.
Champagne D, Hung A, Leclerc O. How pharma can win in a digital world. McKinsey & Company. 2015.
Mukku S. PHP111 Global Evidence Generation-Challenges for the Pharma Industry. Value in Health. 2012; 15(4): A33.
Bhavnani SP, Narula J, Sengupta PP. Mobile technology and the digitization of healthcare. European heart journal. 2016; 37(18): 1428-38.
Tehrani N. Taking control of health care. Zenith International Journal of Multidisciplinary Research, 2015; 10: 978-1.
